What We Do
The Neurofibromatosis Therapeutic Acceleration Program (NTAP) is focused exclusively on improving treatment options for people living with Neurofibromatosis type 1-related plexiform and cutaneous neurofibromas. With the goal of therapeutics always in mind, initiatives span research that probes the basic aspects of tumorgenesis through clinical investigations of drugs that have the highest likelihood of having a positive impact for patients. NTAP’s approach is defined by (1) intense collaboration both within and outside of the neurofibromatosis research community and (2) ongoing critical assessment of the existing needs and opportunities for developing effective plexiform and cutaneous neurofibroma therapeutics.
————————————————————————————————————————————————–
NTAP is pleased to announce the selection of Drs. Nicole Brossier, Suganth Suppiah and Harish Vasudevan as the 2021 class of Francis Collins Scholars. The 2022 funding cycle is now open with a due date for all application materials of December 21, 2021.
With Food and Drug Administration (FDA) approval, selumetinib is now the first effective treatment for children with NF1 associated plexiform neurofibromas that can’t be removed by surgery. Decades of collaborative research culminated in clinical trials of selumetinib for symptomatic cutaneous neurofibromas in children with NF1 that showed unpredicted activity.
NTAP partners with key stakeholders in plexiform and cutaneous neurofibroma therapeutic research to ensure efforts are synergistic and have the greatest possible impact.
